Denise Playdle
University of California, San Francisco
7 Papers
Denise Playdle is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Prostate cancer & Enzalutamide. The author has an hindex of 6, co-authored 7 publications.
Chat about Author
Papers
Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study
Rahul Aggarwal,Jiaoti Huang,Joshi J. Alumkal,Li Zhang,Felix Y. Feng,George Thomas,Alana S. Weinstein,Verena Friedl,Can Zhang,Owen N. Witte,Paul Lloyd,Martin E. Gleave,Christopher P. Evans,Jack F. Youngren,Tomasz M. Beer,Matthew Rettig,Christopher K. Wong,Lawrence D. True,Adam Foye,Denise Playdle,Charles J. Ryan,Primo N. Lara,Kim N. Chi,Vlado Uzunangelov,Artem Sokolov,Yulia Newton,Himisha Beltran,Francesca Demichelis,Mark A. Rubin,Joshua M. Stuart,Eric J. Small +30 more
TL;DR: The near-mutual exclusivity with DNA repair alterations suggests t-SCNC may be a distinct subset of mCRPC, and transcriptional profiling facilitates the identification of t- SCNC and novel therapeutic targets.
Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.
David A. Quigley,Ha X. Dang,Shuang G. Zhao,Paul Lloyd,Rahul Aggarwal,Joshi J. Alumkal,Adam Foye,Vishal Kothari,Marc D. Perry,Adina M. Bailey,Denise Playdle,Travis J. Barnard,Li Zhang,Jin Zhang,Jack F. Youngren,Marcin Cieslik,Abhijit Parolia,Tomasz M. Beer,George Thomas,Kim N. Chi,Martin E. Gleave,Nathan A. Lack,Amina Zoubeidi,Robert E. Reiter,Robert E. Reiter,Matthew Rettig,Owen N. Witte,Charles J. Ryan,Lawrence Fong,Won Kim,Terence W. Friedlander,Jonathan Chou,Haolong Li,Rajdeep Das,Hui Li,Ruhollah Moussavi-Baygi,Hani Goodarzi,Luke A. Gilbert,Primo N. Lara,Christopher P. Evans,Theodore C. Goldstein,Theodore C. Goldstein,Joshua M. Stuart,Scott A. Tomlins,Daniel E. Spratt,R. Keira Cheetham,Donavan T. Cheng,Kyle Kai-How Farh,Julian S. Gehring,Jörg Hakenberg,Arnold Liao,P. G. Febbo,John Shon,Brad Sickler,Serafim Batzoglou,Karen E. Knudsen,Housheng Hansen He,Jiaoti Huang,Alexander W. Wyatt,Scott M. Dehm,Alan Ashworth,Arul M. Chinnaiyan,Christopher G. Maher,Eric J. Small,Felix Y. Feng +64 more
TL;DR: Integrative deep whole-genome and -transcriptome analysis of 101 castration-resistant prostate cancer metastases identified structural variants altering critical regulators of tumorigenesis and progression not detectable by exome approaches, providing a comprehensive view of how structural variations affect critical regulators in metastatic prostate cancer.
658
The DNA methylation landscape of advanced prostate cancer
Shuang G. Zhao,Shuang G. Zhao,William S. Chen,William S. Chen,Haolong Li,Adam Foye,Meng Zhang,Martin Sjöström,Rahul Aggarwal,Denise Playdle,Arnold Liao,Joshi J. Alumkal,Rajdeep Das,Jonathan Chou,Junjie Tony Hua,Travis J. Barnard,Adina M. Bailey,Eric D. Chow,Marc D. Perry,Ha X. Dang,Rendong Yang,Ruhollah Moussavi-Baygi,Li Zhang,Mohammed Alshalalfa,S. Laura Chang,Kathleen E. Houlahan,Kathleen E. Houlahan,Kathleen E. Houlahan,Yu Jia Shiah,Tomasz M. Beer,George Thomas,Kim N. Chi,Martin E. Gleave,Amina Zoubeidi,Robert E. Reiter,Matthew Rettig,Matthew Rettig,Owen N. Witte,M. Yvonne Kim,Lawrence Fong,Daniel E. Spratt,Todd M. Morgan,Rohit Bose,Franklin W. Huang,Hui Li,Lisa N. Chesner,Tanushree R. Shenoy,Hani Goodarzi,Irfan A. Asangani,Shahneen Sandhu,Joshua M. Lang,Nupam P. Mahajan,Primo N. Lara,Christopher P. Evans,Phillip G. Febbo,Serafim Batzoglou,Karen E. Knudsen,Housheng Hansen He,Housheng Hansen He,Jiaoti Huang,Wilbert Zwart,Joseph F. Costello,Jianhua Luo,Scott A. Tomlins,Alexander W. Wyatt,Scott M. Dehm,Alan Ashworth,Luke A. Gilbert,Paul C. Boutros,Paul C. Boutros,Kyle Kai-How Farh,Arul M. Chinnaiyan,Christopher G. Maher,Eric J. Small,David A. Quigley,Felix Y. Feng +75 more
TL;DR: This study identifies genomic regions that are differentially methylated during disease progression and a novel epigenomic subtype and shows that differential methylation during progression preferentially occurs at somatic mutational hotspots and putative regulatory regions.
Erratum: Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer (Cell (2018) 174(3) (758–769.e9), (S0092867418308420) (10.1016/j.cell.2018.06.039))
David A. Quigley,Ha X. Dang,Shuang G. Zhao,Paul Lloyd,Rahul Aggarwal,Joshi J. Alumkal,Adam Foye,Vishal Kothari,Marc D. Perry,Adina M. Bailey,Denise Playdle,Travis J. Barnard,Li Zhang,Jin Zhang,Jack F. Youngren,Marcin Cieslik,Abhijit Parolia,Tomasz M. Beer,George Thomas,Kim N. Chi,Martin E. Gleave,Nathan A. Lack,Amina Zoubeidi,Robert E. Reiter,Matthew Rettig,Owen N. Witte,Charles J. Ryan,Lawrence Fong,Won Kim,Terence W. Friedlander,Jonathan Chou,Haolong Li,Rajdeep Das,Hui Li,Ruhollah Moussavi-Baygi,Hani Goodarzi,Luke A. Gilbert,Primo N. Lara,Christopher P. Evans,Theodore C. Goldstein,Joshua M. Stuart,Scott A. Tomlins,Daniel E. Spratt,R. Keira Cheetham,Donavan T. Cheng,Kyle Kai-How Farh,Julian S. Gehring,Jörg Hakenberg,Arnold Liao,P. G. Febbo,John Shon,Brad Sickler,Serafim Batzoglou,Karen E. Knudsen,Housheng Hansen He,Jiaoti Huang,Alexander W. Wyatt,Scott M. Dehm,Alan Ashworth,Arul M. Chinnaiyan,Christopher G. Maher,Eric J. Small,Felix Y. Feng +62 more
152
Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer.
William S. Chen,William S. Chen,Rahul Aggarwal,Li Zhang,Shuang G. Zhao,George Thomas,Tomasz M. Beer,David A. Quigley,Adam Foye,Denise Playdle,Jiaoti Huang,Paul Lloyd,Eric Lu,Duanchen Sun,Xiangnan Guan,Matthew Rettig,Matthew Rettig,Martin E. Gleave,Christopher P. Evans,Jack F. Youngren,Lawrence D. True,Primo N. Lara,Vishal Kothari,Zheng Xia,Kim N. Chi,Robert E. Reiter,Christopher G. Maher,Felix Y. Feng,Eric J. Small,Joshi J. Alumkal +29 more
TL;DR: Using whole-genome sequencing to assess the association between key driver gene alterations and overall survival (OS) and whole-transcriptome RNA sequencing to identify genomic drivers of enzalutamide resistance sheds new light on clinically relevant genomic alterations in mCRPC and provides a roadmap for the development of new personalized treatment regimens in m CRPC.
140